newsfilter
← Latest News
Business Wire·

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – – Positive blinded pharmacokinetic